30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Bioventus Postpones IPO -

Bioventus is reported to have delayed its US $150MM initial public offering

Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.

Earlier this month, Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017. Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.

Sources: Renaissance Capital, ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.